Nature Medicine | Spoonful of Medicine

Autism express II

There’s a saying in Spanish that roughly translated says “Calamities never arrive alone”. Following John McCain’s statement on the “strong” evidence for a link between vaccines and autism, which Charlotte Schubert blogged about, the ruling in the case of Hannah Poling is a second calamity that is bound to add more fuel to a debate that hasn’t been particularly productive.

The US government’s decision to settle and agree to pay Hannah, who has autistic symptoms, for her care has been immediately heralded as a victory for supporters of the vaccine-autism link, even though officials have been careful to clarify that they didn’t concede that vaccines cause autism.

The government can continue to clarify their position until they go blue in the face but, unfortunately, this ruling is bad news for the science that has debunked the autism-vaccines link, for the cost of health care in the US (which is bound to feel the effect of more settlements of this sort, if this case is accepted as precedent), and for herd immunity (the effectiveness of which may decrease if too many kids in a given pupulation stop being vaccinated).

vaccine.jpg

Comments

  1. Report this comment

    Sergio Stagnaro MD said:

    I am really surprised reading that a few cases of autism followed to vaccine, is considered as a victory for supporters of the vaccine-autism link, even though officials have been careful to clarify that they didn’t concede that vaccines cause autism. As regards autism occurrence the facts are more complex. Firstly, as I referred earlier in Nature website at URL /nm/spoonful/2008/03/gout_gene.html, there are a lot of new concepts in Medicine, unfortunately overlooked by physicians (See later on). Secondly, among millions of vaccinated individuals, only a few are suffering for autism. Thirdly, cerebral disorders may occur only in subjects showing since birth cerebral “real risk”, characterized by local microcirculatory remodelling, based on newborn-pathological, type I, subtype a) ONCOLOGICAL, and b) aspecific, Endoarteriolar Blocking Devices, recognized in a quantitative way wit the aid of Biophysical Semeiotics (1-4) See web sites http://www.semeioticabiofisica.it Biophysical-Semeiotic Constitutions, as well as the http://semeioticabiofisica.it/microangiology. In fact, nowadays clinicians should evaluate and treat first of all such as individuals, recognized bedside, and on very large scale. A lot of other constitutions may be clinically diagnosed in a similar way (1-3). Furthermore, at the base of all these alterations there are both parenchymal and microvascular inherited alterations (n-DNA and mit-DNA), the later parallell the former, according to theory of Angiobiopathy, which completes Tischendorf’s Angiobiotopy theory (1-6). As a matter of fact alterations of microvascular tissue units, and particularly neoformed-pathological, type I, sub-type b), Endoarterial Blocking Devices (EBD) in small arterioles, according to Hammersen, account for the reason that great arterial vessels and particularly microvessels show an impaired motility ,i.e., vasomotility and vasomotion, and than tissue acidosis. (1-6). Indeed, neither all dyslipidaemics nor diabetics present metabolic syndrome, both classic and “variant”, the later I described formerly (1- 6) Certainly, early interventions against these inherited alterations represent the efficacious primary prevention, reducing the risk rheumatic diseases. However, in my long clinical experience, we must go beyond the known risk factors, including vaccination. In fact, Primary Prevention of the most common and dangerous human pathologies, depends clearly by easy and quick bed-side detecting individuals at "real risk” since birth, i.e. involved by well- defined biophysical-semeiotic constitution, assessed clinically in a quantitative way (5). In order to define clinically a particular constitution and related real risk, which does not exclude the presence of a lot of other constitutions, of course, it is necessary to think over the current possibility of gathering at the bed side biophysical-semeiotic data, rich of biological and molecular biological information on the various human organs, tissues and biological systems, so that doctor can describe numerous types of biophysical- semeiotic constitutions, even from the quantitative point of view. Without any doubt, these data can not be observed at all by the aid of neither traditional physical semeiotics nor sophysticated semeiotics, the later on very large scale, of course, unable of carrying molecular-biological events to clinical dimension, which really represents the most original and fertile aspect of Biophysical Semeiotics, which really allows doctor to make correctly early diagnosis.

    References

    1) Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico- Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Travel Factory, Roma, 2004. http://www.travelfactory.it/libro_costituzionisemeiotiche.htm

    2) Stagnaro-Neri M., Stagnaro S. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it/semeiotica_biofisica.htm 2004

    3) Stagnaro S., Stagnaro-Neri M., Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Travel Factory, Roma, 2005. http://www.travelfactory.it/libro_singlepatientbased.htm 2005

    4) Stagnaro S., Auscultatory Percussion of Rheumatic Diseases. X European Congress of Rheumatology. Moscow. 26 June-July, 1983, Proceedings, pg 175 5) Stagnaro S., Auscultatory Percussion Therapeutic Monitoring and Cerebral Dominance in Rheumatology. 2nd World Congress of Inflammation, Antirheumatics, analgesics, immunomodulators. Abstracts, A. Book 1, pg. 116, March 19-22, 1986,Montecarlo.

    6) Stagnaro-Neri M., Stagnaro S., Diagnosi Clinica Precoce dell’Osteoporosi con la Percussione Ascoltata. Clin.Ter. 137, 21-27, 1991 [MEDLINE] .

    7) Stagnaro S., Polimialgia Reumatica Acuta Benigna Variante. Clin. Ter. 118, 193, 1986 [MEDLINE].

    8)Stagnaro Sergio. Newborn-pathological Endoarteriolar Blocking Devices in Diabetic and Dislipidaemic Constitution and Diabetes Primary Prevention. The Lancet. March 06 2007. http://www.thelancet.com/journals/lancet/article/PIIS0140673607603316/